| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Maurizio Del Poeta | Q111269485 |
| P2093 | author name string | Natasha P Medici | |
| P2860 | cites work | A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) | Q24558831 |
| Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis | Q24650911 | ||
| Host-pathogen interactions between the human innate immune system and Candida albicans-understanding and modeling defense and evasion strategies | Q26801655 | ||
| Host immunity to Cryptococcus neoformans | Q26823438 | ||
| Emerging drugs and vaccines for candidemia | Q26828993 | ||
| Dendritic cells in antifungal immunity and vaccine design | Q27001738 | ||
| Antifungal Th Immunity: Growing up in Family | Q27002920 | ||
| Vaccine immunity against fungal infections | Q27009819 | ||
| Adaptive immunity to fungi | Q27025806 | ||
| Current trends in the prevalence of Cryptococcus gattii in the United States and Canada | Q28080670 | ||
| Endemic mycoses: a treatment update | Q28142762 | ||
| Defensins: antimicrobial peptides of innate immunity | Q28204453 | ||
| NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 | Q28298371 | ||
| Collectins: sentinels of innate immunity | Q29392043 | ||
| Hidden killers: human fungal infections | Q29617101 | ||
| NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. | Q30528889 | ||
| Mucosal damage and neutropenia are required for Candida albicans dissemination | Q33320189 | ||
| AIDS-related mycoses: the way forward | Q34030928 | ||
| The direct cost and incidence of systemic fungal infections | Q34116654 | ||
| Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells | Q34350869 | ||
| 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host | Q34390072 | ||
| Coccidioidomycosis in persons infected with HIV type 1. | Q34451074 | ||
| Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans | Q34628045 | ||
| Prospects for development of a vaccine to prevent and control vaginal candidiasis | Q34707478 | ||
| Induced humoral immunity and vaccination against major human fungal pathogens | Q34772215 | ||
| Ten challenges on Cryptococcus and cryptococcosis | Q34960987 | ||
| Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans | Q35065782 | ||
| Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice | Q35066122 | ||
| Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes | Q35131913 | ||
| Vaccines for invasive fungal infections | Q35161720 | ||
| Adaptive immunity to fungi. | Q35164257 | ||
| Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection. | Q35581583 | ||
| Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development | Q35938253 | ||
| Vaccines in the treatment of invasive candidiasis | Q36147010 | ||
| Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans | Q36174591 | ||
| Recent progress in vaccines against fungal diseases | Q36179629 | ||
| Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection | Q36313467 | ||
| Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts | Q36370771 | ||
| A novel glyco-conjugate vaccine against fungal pathogens | Q36402820 | ||
| Advances in combating fungal diseases: vaccines on the threshold | Q36406460 | ||
| Towards a vaccine for Cryptococcus neoformans: principles and caveats. | Q36476690 | ||
| Fungal cell wall vaccines: an update | Q36525342 | ||
| Prospects for development of vaccines against fungal diseases | Q36527215 | ||
| Immunological aspects of Candida and Aspergillus systemic fungal infections | Q36587261 | ||
| Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis | Q36598058 | ||
| Invasive fungal infections in acute leukemia | Q36612597 | ||
| Nosocomial fungal infections: epidemiology, diagnosis, and treatment | Q36825717 | ||
| Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity | Q36988205 | ||
| Antifungal management in cancer patients | Q37009912 | ||
| Fungal vaccines: real progress from real challenges | Q37067893 | ||
| Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis | Q37116545 | ||
| Immune response to fungal infections | Q37195455 | ||
| Developing a vaccine against aspergillosis | Q37770560 | ||
| Direct microbicidal activity of cytotoxic T-lymphocytes | Q37771265 | ||
| T-cell Subsets and Antifungal Host Defenses | Q37803134 | ||
| Innate and adaptive antifungal immune responses: partners on an equal footing | Q37911539 | ||
| Systems biology of infectious diseases: a focus on fungal infections | Q37926002 | ||
| Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders | Q37999620 | ||
| From memory to antifungal vaccine design | Q38014632 | ||
| Vaccination of immunocompromised patients | Q38050852 | ||
| Fungal pathogens-a sweet and sour treat for toll-like receptors | Q38063202 | ||
| Cryptococcus antigens and immune responses: implications for a vaccine | Q38155197 | ||
| Invasive fungal infections in the ICU: how to approach, how to treat. | Q38180287 | ||
| A neglected epidemic: fungal infections in HIV/AIDS. | Q38188277 | ||
| Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review. | Q38195802 | ||
| Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects | Q38232781 | ||
| Adjuvants and delivery systems for antifungal vaccines: current state and future developments | Q38264288 | ||
| Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis | Q38286732 | ||
| Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth | Q39517451 | ||
| Prospects for the development of fungal vaccines. | Q39820834 | ||
| Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection | Q41004226 | ||
| Paracoccidioides brasiliensis Infection in Small Wild Mammals. | Q41077862 | ||
| Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model | Q41141114 | ||
| Infectious Disease. How to bolster the antifungal pipeline | Q41378447 | ||
| Therapeutic vaccine using a monoclonal antibody against a 70-kDa glycoprotein in mice infected with highly virulent Sporothrix schenckii and Sporothrix brasiliensis | Q41586099 | ||
| The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system | Q41874883 | ||
| Immunity to fungi | Q42553468 | ||
| T cell vaccination in mice with invasive pulmonary aspergillosis. | Q43413736 | ||
| DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis induces long-term protection in presence of regulatory T cells. | Q43846934 | ||
| Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis | Q44116601 | ||
| Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital | Q46985833 | ||
| A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. | Q47804487 | ||
| Isolation of Paracoccidioides brasiliensis from armadillos (Dasypus noveminctus) captured in an endemic area of paracoccidioidomycosis | Q48476949 | ||
| Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. | Q51015235 | ||
| Proinflammatory response of immature human dendritic cells is mediated by dectin-1 after exposure to Aspergillus fumigatus germ tubes. | Q54546379 | ||
| Immunity to fungal infections | Q58855371 | ||
| Passive immunization with monoclonal antibody against a 70-kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis | Q79808400 | ||
| Immunization with P10 peptide increases specific immunity and protects immunosuppressed BALB/c mice infected with virulent yeasts of Paracoccidioides brasiliensis | Q87610983 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fungal infectious disease | Q464067 |
| vaccine development | Q27133094 | ||
| fungal vaccines | Q58623858 | ||
| preventive health services | Q65732032 | ||
| biomedical investigative technique | Q66648976 | ||
| host microbial interaction | Q68260314 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 966-73 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Memórias do Instituto Oswaldo Cruz | Q15760238 |
| P1476 | title | New insights on the development of fungal vaccines: from immunity to recent challenges | |
| P478 | volume | 110 |
| Q39338332 | Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi. |
| Q28818603 | Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis |
| Q39390619 | Cancer immunotherapy: Breakthrough or "deja vu, all over again"? |
| Q65000937 | Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction. |
| Q40045680 | Future Research Priorities in Fungal Resistance |
| Q89977631 | Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies |
| Q40183778 | Nanoparticle-Based Mycosis Vaccine |
| Q38692399 | Promising immunotherapy against fungal diseases |
| Q57471513 | Special Issue " and Sporotrichosis" |
| Q64118476 | Targeting Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model |
Search more.